Le Lézard
Classified in: Business
Subject: ATY

Scott+Scott Attorneys at Law LLP Announces Investigation into Menlo Therapeutics Inc. (MNLO)


NEW YORK, June 19, 2018 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating whether Menlo Therapeutics Inc. ("Menlo" or the "Company") (NASDAQ: MNLO) or certain of its officers and directors violated federal securities laws.  If you purchased Menlo stock in or after the Company's January 2018 initial public offering ("IPO"), you are encouraged to contact a Scott+Scott attorney at (844) 818-6982 for more information.

Menlo is a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough.

This investigation concerns whether Menlo's filings with the U.S. Securities and Exchange Commission in connection with the IPO contained untrue statements of material fact or omitted material information, specifically regarding the Company's second Phase 2 clinical trial of patients treated with serlopitant.

On April 9, 2018, Menlo disclosed that Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis failed to meet its primary or key secondary efficacy endpoints.  The trial showed no statistically significant difference between patients treated with serlopitant and patients treated with placebo. 

On this news, the price of Menlo stock closed at $8.17, a 76.8% decline from its previous close price of $35.22, and a 51% decline from the IPO price of $17.00.

What You Can Do

If you purchased Menlo common stock, and you wish to discuss this investigation, please contact attorney Joe Pettigrew at (844) 818-6982, or at [email protected], or visit the Menlo investigation page on our website at https://scott-scott.com/investigation/menlo/.

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States.  The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

Attorney Advertising

CONTACT:

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
230 Park Ave, 17th Fl, NY, NY 10169
(844) 818-6982
[email protected] 

SOURCE Scott+Scott Attorneys at Law LLP


These press releases may also interest you

at 01:26
Rickard Gustafson, President and CEO: "Our first quarter performance marked another step towards a more resilient and competitive SKF. In soft market conditions, we delivered a strong adjusted operating margin of 13.4%, somewhat ahead of Q1 2023. The...

at 01:15
The first-ever public auction of the epic satoshi held by CoinEx, the leading global cryptocurrency exchange, ended on April 25, 2024, at 16:00 (UTC). As the first example shown in history, the auction attracted global users for 35 bids, and the epic...

25 avr 2024
AZZ Inc. , the leading independent provider of hot-dip galvanizing and coil coating solutions, today announced the pricing of its underwritten public offering of 4,000,000 shares of common stock at a public offering price per share of $70.00, for...

25 avr 2024
CarLotz, Inc.  Accused of Misleading Investors On March 29, 2024, the defendants' motion to dismiss in the pending securities class...

25 avr 2024
TSX VENTURE COMPANIES BULLETIN V2024-1200 LEONOVUS INC. ("LTV.WT")BULLETIN TYPE:  Warrant Expiry-DelistBULLETIN DATE:  April 25, 2024TSX Venture Tier 2 Company Effective at the opening, May 2, 2024, the Share Purchase Warrants of the Company will...

25 avr 2024
Greenbrook TMS Inc. ("Greenbrook" or the "Company") today announced its fiscal year ended December 31, 2023 ("Fiscal 2023") operational and financial results. All values in this news release are in United States dollars, unless otherwise stated....



News published on and distributed by: